The U.S. Department of Veterans Affairs (VA) is launching a clinical study to evaluate MDMA-assisted therapy for veterans. The trial focuses on assessing the safety and potential effectiveness of methylenedioxymethamphetamine (MDMA) combined with therapy for post-traumatic stress disorder (PTSD). The VA also is evaluating how MDMA-assisted treatment may affect participants with severe mental health disorders and people with alcohol use disorder.
According to reporting from multiple outlets, the study is intended as a structured review of both safety and efficacy, reflecting the VA’s interest in understanding the risks and benefits of MDMA in a therapeutic setting. The trial includes veterans as the target population and centers on PTSD, with alcohol use disorder also included in the research scope.
The VA describes the effort as a trial review, indicating that findings are expected to inform future decisions about whether MDMA-assisted therapy could be used more broadly for eligible veterans. No final results are reported in the coverage.
